Mabtas RA 500 mg Injection
426,96$
107,09$
Mabtas RA 500 mg injection is a targeted monoclonal antibody therapy designed to address various immune-related disorders, particularly in oncology. This medication is primarily utilized in the treatment of specific types of cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia, by inhibiting the growth of malignant cells. By binding to specific antigens on the surface of cancerous cells, Mabtas RA disrupts their survival signals, promoting cell death and enhancing the body's immune response against the tumor. Patients receiving this treatment should be monitored for potential side effects, including infusion reactions and increased susceptibility to infections, due to its impact on immune function. It is crucial for individuals with a history of severe allergies or those currently undergoing other immunosuppressive therapies to discuss their full medical history with their healthcare provider before starting this treatment. Mabtas RA represents a significant advancement in cancer care, offering hope for improved outcomes in patients battling these challenging conditions. Always consult your healthcare professional to understand the full spectrum of benefits and risks associated with this injection.
Cantidad
Active Pharmaceutical Ingredient
Uses
• Mabtas ra 500 mg injection is primarily indicated for the treatment of Non-Hodgkin lymphoma (NHL). This type of cancer affects the lymphatic system, and the medication works by targeting specific cells to help manage the disease. Patients receiving Mabtas ra 500 mg injection may experience improved outcomes in their treatment regimen. It is often used in conjunction with other therapies for a comprehensive approach.
• In addition to NHL, Mabtas ra 500 mg injection is effective in treating rheumatoid arthritis. This chronic inflammatory condition can significantly impact a person's quality of life. The injection helps reduce inflammation and pain associated with the disease, enabling better mobility and function for patients. Regular administration of Mabtas ra 500 mg injection may lead to improved joint health over time.
• Mabtas ra 500 mg injection is also utilized in the management of chronic lymphocytic leukaemia (CLL). This form of blood cancer requires targeted therapy for effective treatment. The injection assists in controlling the proliferation of cancerous cells, thereby stabilizing the disease. Patients may find that Mabtas ra 500 mg injection enhances their overall treatment plan and helps manage symptoms.
• Furthermore, Mabtas ra 500 mg injection is indicated for conditions such as granulomatosis with polyangiitis and microscopic polyangiitis. These rare autoimmune diseases can lead to serious complications if left untreated. By using Mabtas ra 500 mg injection, healthcare providers aim to suppress the immune response and reduce inflammation. This targeted approach can help patients achieve better disease management and improve their quality of life.
Benefits
Non-Hodgkin lymphoma (NHL): Non-Hodgkin's lymphoma is a form of cancer that affects the white blood cells in the body. These cells are responsible for preventing infections. Mabtas RA 500 mg Injection has been demonstrated to reduce the immune response and relieve pain and inflammation. It also can kill cancer cells and prevent their further growth. To prevent the spread of infection, it is advisable to avoid crowds and to wash your hands frequently. It is recommended that patients consume an adequate quantity of fluids unless otherwise advised by their physician. Rheumatoid arthritis: Mabtas RA 500 mg is an immunosuppressant that is used to treat rheumatoid arthritis. It is administered in a dose and frequency that is tailored to the patient's condition. This is determined by the physician. It is crucial to adhere to the physician's instructions and to promptly report any adverse effects, including fever, chills, or other symptoms, to the physician. Blood cancer (Chronic lymphocytic leukaemia): Leukaemia, also known as blood cancer, is a malignant neoplasm of the haematopoietic tissues that impairs the body's ability to combat infection. Mabtas RA 500 Injection is a chemotherapeutic agent that kills or inhibits the proliferation of malignant cells and is effective in the treatment of leukaemia. However, it is important to discuss the potential side effects and benefits of this medication with a qualified healthcare professional. It is also essential to inform your doctor of any adverse effects that may arise during treatment. Granulomatosis with polyangiitis: Granulomatosis with polyangiitis (GPA) is a condition that causes inflammation of the blood vessels of the ears, nose, throat, lungs, and kidneys. In this condition, the blood flow to these areas may be reduced, which can lead to their damage. Mabtas RA 500 mg Injection is an effective treatment that helps reduce inflammation, pain, and swelling and prevents further damage. This improves the quality of life of those affected by GPA. Microscopic polyangiitis: Microscopic polyangiitis is an autoimmune disease that affects the small blood vessels and may be caused by an imbalance in the immune system. Mabtas RA 500 Injection reduces the immune response and improves inflammation. This helps to heal the condition and to alleviate discomfort.
Side Effects
Mabtas RA 500 mg Injection can cause various adverse effects that can differ from one person to another. Some of the adverse effects of the drug are listed below.
Most Common Side Effects
• Low Immunity
• Nausea
• Tinnitus
• Muscle Pain and Stiffness
• Face Swelling
• Low Blood Count of White Blood Cells and Red Blood Cells
• Increase in Glucose Levels in Blood
• Headache
Common Side Effects
• Skin Reactions
• Heart Problems
• Infections
• Allergies
How To Use
The administration of Mabtas RA 500 mg Injection is typically conducted by a medical professional, such as a doctor or nurse, in a medical facility, such as a hospital or clinic. It is not advisable to administer the product independently, and it is important to adhere to the instructions provided by a qualified healthcare professional.
Safety Advice
• Alcohol: Caution should be exercised when drinking alcohol with Mabtas RA 500 mg. Please consult your doctor.
• Kidney: Mabtas RA 500 Injection is likely to be safe in patients with kidney disease. The limited data available suggest that dose adjustment of Vortuxi Solution for Infusion may not be necessary for these patients. Please consult your doctor.
• Breastfeeding: Mabtas RA 500 mg Injection is likely to be safe to use while breast-feeding, and limited human statistics support that the drug now no longer poses a good risk to the baby.
• Liver: Mabtas RA 500 mg Injection is not recommended in patients with active liver disease or those who have had viral hepatitis. Please consult your doctor.
• Pregnancy: Mabtas RA 500 mg Injection may not be safe for use during pregnancy. Although there is limited human research, animal research has shown dangerous effects on the growing baby. Your doctor will weigh up the benefits and potential risks before prescribing it to you. Please consult your doctor.
• Driving: It is not known whether Mabtas RA 500 mg affects your ability to drive. Do not drive if you experience symptoms that affect your ability to concentrate and react.